Compare American Electric Power Company Inc (AEP) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Electric Power Company Inc vs Cytokinetics Inc — how do they compare? American Electric Power Company Inc trades at $136.44 (market cap $74.83B), while Cytokinetics Inc trades at $83.61 (market cap $11.62B). The key difference: American Electric Power Company Inc is far larger — about 6.4× Cytokinetics Inc's market cap, and American Electric Power Company Inc pays a 2.76% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| AEP | CYTK | |
|---|---|---|
Market Cap | $74.83B | $11.62B |
Sector | Utilities | Technology |
52-Week High | $138.69 | $87.26 |
52-Week Low | $103.96 | $33.23 |
Enterprise Value | $126.09B | $12.09B |
Dividend Yield | 2.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEP trades at $137.53, down 0.71% on the day, with strong analyst support (64% buy ratings) and a $142.82 consensus price target. The stock shows bullish technical momentum with recent earnings beats and robust revenue growth, climbing from $19.7B in 2024 to $21.9B in 2025. AEP benefits from AI-driven electricity demand and a $78B capital plan for grid expansion.
Outlook remains positive given AEP's strategic positioning in energy infrastructure, though risks include high capital expenditures and debt levels. The current valuation at 20.12x P/E appears reasonable for a utility with stable earnings growth and dividend payments, supporting a constructive view for long-term investors.
CYTK trades at $85.57, down 1.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported a net loss of $784.96 million in 2025, with revenue of $88.04 million, but recent news highlights the European launch of MYQORZO and upcoming clinical data presentations at the ESC Congress 2026, indicating growth potential.
The outlook for CYTK is driven by product launches and clinical milestones, but high valuation (P/S 98.09) and persistent losses pose risks. Analyst consensus is overwhelmingly bullish with a $110.60 price target, though investors must weigh the speculative nature against execution risks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
